GENOMICS BIOSCI & TECH. CO.,LTD. Financials Genomics BioSci & Tech. Co.,Ltd.
Equities
4195
TW0004195003
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20 TWD | -0.99% |
|
+3.90% | -3.85% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 714.4 | 743.9 | 1,117 | 1,126 | 1,257 | 1,507 |
| Enterprise Value (EV) 1 | 424.9 | 375.6 | 660 | 1,105 | 1,169 | 1,537 |
| P/E ratio | -11.8 x | 8.83 x | 1,932 x | 60.8 x | 17.3 x | -8.8 x |
| Yield | - | 9.34% | - | - | 0.5% | - |
| Capitalization / Revenue | 1.63 x | 1.74 x | 2.52 x | 2.89 x | 3 x | 3.8 x |
| EV / Revenue | 0.97 x | 0.88 x | 1.49 x | 2.83 x | 2.79 x | 3.88 x |
| EV / EBITDA | -16.9 x | 8.88 x | 17.5 x | 1,358 x | -216 x | -31.4 x |
| EV / FCF | 6.31 x | 4.05 x | -11.4 x | -8.93 x | -11.2 x | -7 x |
| FCF Yield | 15.9% | 24.7% | -8.76% | -11.2% | -8.97% | -14.3% |
| Price to Book | 1.18 x | 1.08 x | 1.66 x | 1.66 x | 1.59 x | 1.97 x |
| Nbr of stocks (in thousands) | 60,230 | 60,230 | 60,230 | 60,230 | 64,288 | 72,448 |
| Reference price 2 | 11.86 | 12.35 | 18.55 | 18.69 | 19.56 | 20.80 |
| Announcement Date | 30/04/19 | 30/04/20 | 27/04/21 | 26/04/22 | 25/04/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 438.7 | 427.7 | 443.2 | 390 | 419 | 396.1 |
| EBITDA 1 | -25.17 | 42.31 | 37.72 | 0.814 | -5.413 | -49.01 |
| EBIT 1 | -64.68 | 8.491 | 6.596 | -28.66 | -33.52 | -81.9 |
| Operating Margin | -14.74% | 1.99% | 1.49% | -7.35% | -8% | -20.67% |
| Earnings before Tax (EBT) 1 | -67.37 | 12.89 | -3.103 | 12.09 | 72.26 | -167.9 |
| Net income 1 | -60.55 | 84.94 | 0.619 | 18.74 | 71.6 | -168.1 |
| Net margin | -13.8% | 19.86% | 0.14% | 4.81% | 17.09% | -42.43% |
| EPS 2 | -1.009 | 1.399 | 0.009600 | 0.3076 | 1.127 | -2.364 |
| Free Cash Flow 1 | 67.38 | 92.72 | -57.84 | -123.7 | -104.8 | -219.7 |
| FCF margin | 15.36% | 21.68% | -13.05% | -31.73% | -25.02% | -55.45% |
| FCF Conversion (EBITDA) | - | 219.17% | - | - | - | - |
| FCF Conversion (Net income) | - | 109.17% | - | - | - | - |
| Dividend per Share | - | 1.153 | - | - | 0.0980 | - |
| Announcement Date | 30/04/19 | 30/04/20 | 27/04/21 | 26/04/22 | 25/04/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 30.6 |
| Net Cash position 1 | 289 | 368 | 457 | 21 | 88.2 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.6239 x |
| Free Cash Flow 1 | 67.4 | 92.7 | -57.8 | -124 | -105 | -220 |
| ROE (net income / shareholders' equity) | -9.61% | 1.24% | -0.18% | 1.52% | 9.75% | -21.6% |
| ROA (Net income/ Total Assets) | -4.52% | 0.6% | 0.4% | -1.78% | -2.12% | -4.54% |
| Assets 1 | 1,339 | 14,220 | 155.4 | -1,051 | -3,372 | 3,700 |
| Book Value Per Share 2 | 10.10 | 11.50 | 11.20 | 11.30 | 12.30 | 10.60 |
| Cash Flow per Share 2 | 4.000 | 6.660 | 7.920 | 1.780 | 4.930 | 3.490 |
| Capex 1 | 18.3 | 21 | 42.7 | 93.6 | 94.1 | 150 |
| Capex / Sales | 4.16% | 4.91% | 9.63% | 24% | 22.45% | 37.93% |
| Announcement Date | 30/04/19 | 30/04/20 | 27/04/21 | 26/04/22 | 25/04/23 | 15/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -3.85% | 45.35M | |
| +39.78% | 54.04B | |
| +43.57% | 41.96B | |
| -1.11% | 41.92B | |
| -7.59% | 28.35B | |
| +12.78% | 26.35B | |
| -22.09% | 19B | |
| +7.75% | 13B | |
| +28.09% | 12.28B | |
| +25.10% | 12.19B |
- Stock Market
- Equities
- 4195 Stock
- Financials Genomics BioSci & Tech. Co.,Ltd.